What if you could kill cancer cells by inhibiting the enzyme that enables their uncontrolled division?

Scientific research has shown that telomerase activity is increased in malignant stem and progenitor cells in the bone marrow. Inhibiting telomerase activity aims to potentially reduce proliferation and induce death of malignant cells.

Geron is exploring the broad potential of telomerase inhibition across multiple hematologic malignancies.

Our pipeline

We are exploring the broad potential of telomerase inhibition across multiple myeloid hematologic malignancies.

Geron Pipeline

*TELOMERE is expected to begin after an appropriate dose of single agent imetelstat in AML has been identified in the IMpress study.

Ongoing clinical trials:

Phase 3 trial in JAK inhibitor relapsed/refractory myelofibrosis (MF)
Learn more about the study
Phase 1 trial in intermediate or high-risk frontline myelofibrosis (MF)
Learn more about the study
Patients

We are on a mission to extend and enhance patients’ lives

Discover more about our commitment to patients